Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPension (IS)Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Harvard Bioscience (HBIO) Short-Term Debt repayments (2021 - 2025)

Harvard Bioscience (HBIO) has disclosed Short-Term Debt repayments for 5 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • Quarterly Short-Term Debt repayments changed N/A to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.6 million through Dec 2025, up 396.08% year-over-year, with the annual reading at $12.6 million for FY2025, 396.08% up from the prior year.
  • Short-Term Debt repayments for Q4 2025 was $12.6 million at Harvard Bioscience, up from $2.0 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $12.6 million in Q4 2025, with the low at -$1.8 million in Q4 2021.
  • Average Short-Term Debt repayments over 5 years is $2.9 million, with a median of $2.5 million recorded in 2023.
  • The sharpest move saw Short-Term Debt repayments skyrocketed 197.22% in 2022, then plummeted 80.0% in 2024.
  • Over 5 years, Short-Term Debt repayments stood at -$1.8 million in 2021, then surged by 197.22% to $1.8 million in 2022, then surged by 42.86% to $2.5 million in 2023, then decreased by 18.0% to $2.0 million in 2024, then skyrocketed by 517.07% to $12.6 million in 2025.
  • According to Business Quant data, Short-Term Debt repayments over the past three periods came in at $12.6 million, $2.0 million, and $500000.0 for Q4 2025, Q2 2024, and Q1 2024 respectively.